scholarly journals The Impact of Antihypertensive Drug Therapy on Endotoxemia in Elderly Patients with Chronic Kidney Disease

2011 ◽  
Vol 6 (10) ◽  
pp. 2389-2394 ◽  
Author(s):  
Stephen G. John ◽  
Paul J. Owen ◽  
Laura E. A. Harrison ◽  
Cheuk-Chun Szeto ◽  
Ka-Bik Lai ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Drug Therapy ◽  
Kidney Disease ◽  
Elderly Patients ◽  
Antihypertensive Drug ◽  
Antihypertensive Drug Therapy ◽  
The Impact

scholarly journals The chaos of hypertension guidelines for chronic kidney disease patients

2019 ◽  
Vol 12 (6) ◽  
pp. 771-777 ◽  
Author(s):  
Esmeralda Castillo-Rodriguez ◽  
Beatriz Fernandez-Fernandez ◽  
Raquel Alegre-Bellassai ◽  
Mehmet Kanbay ◽  
Alberto Ortiz
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Drug Therapy ◽  
Kidney Disease ◽  
Antihypertensive Drug ◽  
Secondary Hypertension ◽  
Antihypertensive Drug Therapy ◽  
Hypertensive Drug ◽  
Definition Of ◽  
Current Guidelines

Abstract Three major guidelines deal with blood pressure thresholds and targets for antihypertensive drug therapy in chronic kidney disease (CKD) patients: the 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease; the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults; and the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. However, a careful reading of the three guidelines leaves the practicing physician confused about the definition of CKD, how hypertension and secondary hypertension should be diagnosed in CKD patients and what the blood pressure thresholds, targets and compelling indications of antihypertensive drug therapy should be for this population. Current guidelines refer to different CKD populations and propose different definitions of hypertension, different thresholds to initiate antihypertensive therapy in CKD patients and different BP targets compelling antihypertensive drug use. The different bodies producing guidelines should work together towards a unified definition of CKD, a unified concept of hypertension and unified BP thresholds and targets for hypertensive drug therapy for CKD patients. Otherwise they risk promoting confusion and therapeutic nihilism among physicians and patients.

scholarly journals THE IMPACT OF ANTIHYPERTENSIVE DRUG THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A PROSPECTIVE OBSERVATIONAL COHORT STUDY

2019 ◽  
pp. 10-15
Author(s):  
ALMAS SAFINA KAUSER ◽  
HABEEB UNNISA ◽  
AFIFA NAMREEN ◽  
AYESHA SABA ◽  
JAVED AKHTAR ANSARI
Keyword(s):  
Chronic Kidney Disease ◽  
Cohort Study ◽  
Drug Therapy ◽  
Kidney Disease ◽  
Antihypertensive Drugs ◽  
Observational Cohort Study ◽  
Antihypertensive Drug Therapy ◽  
Prospective Observational Cohort Study ◽  
Observational Cohort ◽  
The Impact

Objective: Hypertension (HTN) is both a cause and an effect of chronic kidney disease (CKD). To adequately control blood pressure (BP) in CKD, choosing antihypertensive strategies with the highest nephro-protective effect is crucial for preventing or reversing end-stage renal disease (ESRD) progression and reducing cardiovascular disease (CVD) risk. The present study was therefore designed to evaluate the impact of clinical use of antihypertensive drug therapy in patients with CKD and ESRD. Methods: It is a prospective observational cohort study. The patients were divided into two cohorts i.e.; non-dialysis dependent (NDD) and dialysis-dependent (DD) CKD. This study was conducted for six months in the Nephrology department, Osmania General Hospital, Hyderabad, India. The data collected and entered into Microsoft Excel (2007) and mean, SD and range were calculated using SPSS version 25. Results: Antihypertensive drugs were prescribed alone or in combination based on the co-morbidities associated with CKD and HTN. Loop diuretics (Furosemide and Torsemide) and calcium channel blocker (Amlodipine, Nifedipine and Cilnidipine) were most commonly prescribed antihypertensive drugs. Triple therapy (44.11%) was prescribed mostly in both the cohorts (NDD = 16.66%+DD = 27.45%) of which calcium channel blockers+loop diuretic+sympatholytic accounts for 19.16% (NDD = 5.88%+DD = 13.73%).  Conclusion: The practice of prescribing antihypertensive drugs for the management of HTN and to achieve BP targets in CKD and ESRD remains uncertain. The development of new and revised guidelines is needed to reduce inappropriate variations in practice and promote better delivery of evidence-based treatment.

scholarly journals The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients

2017 ◽  
Vol 10 (3) ◽  
pp. 375-380
Author(s):  
Fanny Lepeytre ◽  
Héloise Cardinal ◽  
Lorraine Fradette ◽  
Jacobien Verhave ◽  
Marc Dorais ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Drug Therapy ◽  
Kidney Disease ◽  
Renal Protection ◽  
The Impact ◽  
Cardioprotective Drug

scholarly journals ANTIHYPERTENSIVE DRUG THERAPY BETWEEN ELDERLY PATIENTS IN A RURAL AREA OF PORTUGAL

2021 ◽  
Vol 39 (Supplement 1) ◽  
pp. e95
Author(s):  
Mykhailo Iashchuk ◽  
Juan Manuel Urbano Galvez ◽  
Lorena Lozano Real ◽  
Paula Sofia Araujo
Keyword(s):  
Drug Therapy ◽  
Elderly Patients ◽  
Rural Area ◽  
Antihypertensive Drug ◽  
Antihypertensive Drug Therapy

The impact of intradialytic exercise on immune cells expressing CCR5+ in patients with chronic kidney disease: A cross-over trial

2021 ◽  
pp. 039139882110013
Author(s):  
Maria Isabel Fuhro ◽  
Francini P Andrade ◽  
Gilson P Dorneles ◽  
Fabio S Lira ◽  
Pedro RT Romão ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
T Cells ◽  
Kidney Disease ◽  
Elderly Patients ◽  
Moderate Intensity ◽  
Exercise Session ◽  
Moderate Intensity Exercise ◽  
Single Bout ◽  
Intradialytic Exercise ◽  
The Impact

The C-C chemokine receptor type 5 (CCR5) plays a role in the immunopathogenesis of chronic kidney disease (CKD). Exercise has anti-inflammatory properties that may contribute to the rehabilitation of CKD patients. To date, the impact of the intradialytic exercise on CCR5 expression in monocytes and lymphocytes of CKD patients is unknown. We aimed to evaluate the effects of an acute intradialytic moderate-intensity exercise on CD4+CCR5+ T-cells and CD14+CCR5+ monocytes of elderly individuals with Chronic Kidney Disease (CKD). Eight CKD elderly patients performed a single bout of 20 min intradialytic exercise and a control hemodialysis (HD) session. Blood samples were collected at baseline, during and immediately after the trials. HD therapy increased the peripheral frequency of CD4+CCR5+ T-cells. The systemic CCL5 levels and the peripheral CD14+CCR5+ proportions increased during and after HD therapy. No significant alterations in CD4+CCR5+ and CD14+CCR5+ proportions or CCL5 levels were identified in CKD patients during and after intradialytic exercise. A negative correlation between the peripheral frequency of CD14+CCR5+ and the creatinine levels was identified in the intradialytic exercise session. A single moderate-intensity intradialytic exercise imposes an immunomodulatory impact in CKD elderly patients, preventing an excessive inflammatory response induced by hemodialysis.

Sign in / Sign up

Export Citation Format

Share Document